← Leaderboards
Liang Cao
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsResponseTumorEvaluationCellsBiological MarkersClinical TrialsLaboratoriesValidationNeoplastic CellBaseInvestigationTechnologyNew Therapeutic TargetRhabdomyosarcomaMutationBiological ModelsCytokineCorrelative StudyBiologicalIgf1r GeneAntibodiesIn VivoDesign
Grant awards (35)
Biomarker Investigations for Clinical Trials$945,320
ZIC · FY2023 · CA · contact PI
Omics Technology facility$945,320
ZIC · FY2023 · CA · contact PI
Biomarker Investigations for Clinical Trials$822,832
ZIC · FY2022 · CA · contact PI
Omics Technology facility$822,832
ZIC · FY2022 · CA · contact PI
Biomarker Investigations for Clinical Trials$1,530,925
ZIC · FY2021 · CA · contact PI
Omics Technology facility$170,103
ZIC · FY2021 · CA · contact PI
Biomarker Investigations for Clinical Trials$1,025,905
ZIC · FY2020 · CA · contact PI
Biomarker Investigations for Clinical Trials$959,273
ZIC · FY2019 · CA · contact PI
Biomarker Investigations for Clinical Trials$855,747
ZIC · FY2018 · CA · contact PI
Biomarker Investigations for Clinical Trials$829,776
ZIC · FY2017 · CA · contact PI
Biomarker investigations for Clinical Trials$757,505
ZIC · FY2016 · CA · contact PI
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma$84,167
ZIC · FY2016 · CA · contact PI
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations$644,511
ZIC · FY2015 · CA · contact PI
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma$145,014
ZIC · FY2015 · CA · contact PI
Molecular Pathogenic Mechanism of Rhabdomyosarcoma$16,112
ZIA · FY2015 · CA · contact PI
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations$558,923
ZIC · FY2014 · CA · contact PI
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma$125,758
ZIC · FY2014 · CA · contact PI
Molecular Pathogenic Mechanism of Rhabdomyosarcoma$13,973
ZIA · FY2014 · CA · contact PI
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations$335,625
ZIC · FY2013 · CA · contact PI
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma$268,500
ZIC · FY2013 · CA · contact PI
Molecular Pathogenic Mechanism of Rhabdomyosarcoma$67,125
ZIA · FY2013 · CA · contact PI
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations$356,520
ZIC · FY2012 · CA · contact PI
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma$285,217
ZIC · FY2012 · CA · contact PI
Molecular Pathogenic Mechanism of Rhabdomyosarcoma$71,304
ZIA · FY2012 · CA · contact PI
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations$330,540
ZIC · FY2011 · CA · contact PI
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma$198,324
ZIC · FY2011 · CA · contact PI
Molecular Pathogenic Mechanism of Rhabdomyosarcoma$132,216
ZIA · FY2011 · CA · contact PI
Molecular Pathogenic Mechanism of Rhabdomyosarcoma$254,720
ZIA · FY2010 · CA · contact PI
Predictive Biomarkers and Mechanism of Action for Anti-IGF1R Agents for Cancer$191,041
ZIC · FY2010 · CA · contact PI
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations$191,041
ZIC · FY2010 · CA · contact PI
Molecular Pathogenic Mechanism of Rhabdomyosarcoma$241,823
ZIA · FY2009 · CA · contact PI
Predictive Biomarkers and Mechanism of Action for Anti-IGF1R Agents for Cancer$181,367
ZIC · FY2009 · CA · contact PI
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations$181,367
ZIC · FY2009 · CA · contact PI
Predictive Biomarkers and Mechanism of Action for Anti-IGF1R Agents for Cancer$316,941
Z01 · FY2008 · CA · contact PI
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations$211,294
Z01 · FY2008 · CA · contact PI